Source:http://linkedlifedata.com/resource/pubmed/id/19738457
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2009-10-28
|
pubmed:abstractText |
Tenascin XB (TNXB) was previously identified as a gene that is more highly expressed in malignant mesothelioma compared with ovarian/peritoneal serous carcinoma based on gene expression array analysis. The objective of this study was to validate this finding at the mRNA and protein levels. Effusions (n = 91; 71 ovarian carcinomas, 10 breast carcinomas, and 10 malignant mesotheliomas) were assayed for TNXB mRNA expression using quantitative polymerase chain reaction. Tenascin-X protein expression was studied in 183 effusions (137 carcinomas of different origin, 37 mesotheliomas, and 9 reactive effusions) and 178 solid lesions (122 ovarian/peritoneal carcinomas and 56 mesotheliomas) using immunohistochemistry. Quantitative polymerase chain reaction analysis showed significantly higher TNXB mRNA level in mesotheliomas compared with ovarian and breast carcinomas (P < 0.001). By immunohistochemistry, tenascin-X protein expression was significantly higher in malignant mesothelioma compared with metastatic carcinoma in effusions (34 of 37 vs. 31 of 137 positive cases; sensitivity = 92% and specificity = 77%; P < 0.001). Reactive mesothelial cells had focal or no tenascin-X expression. Tenascin-X protein was detected in 41 of 56 mesothelioma biopsy specimens and was uniformly absent from all 122 ovarian carcinomas (sensitivity = 73% and specificity = 100%; P < 0.001). Our data suggest that tenascin-X may be a new diagnostic marker of malignant mesothelioma in the differential diagnosis of cancers involving the serosal cavities, particularly in the differential diagnosis between this tumor and ovarian/peritoneal serous carcinoma.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Tenascin,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/tenascin X
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1532-0979
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
33
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1673-82
|
pubmed:dateRevised |
2011-9-16
|
pubmed:meshHeading |
pubmed-meshheading:19738457-Adenocarcinoma,
pubmed-meshheading:19738457-Breast Neoplasms,
pubmed-meshheading:19738457-Female,
pubmed-meshheading:19738457-Gene Expression,
pubmed-meshheading:19738457-Humans,
pubmed-meshheading:19738457-Male,
pubmed-meshheading:19738457-Mesothelioma,
pubmed-meshheading:19738457-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:19738457-Pleural Effusion, Malignant,
pubmed-meshheading:19738457-Predictive Value of Tests,
pubmed-meshheading:19738457-RNA, Messenger,
pubmed-meshheading:19738457-RNA, Neoplasm,
pubmed-meshheading:19738457-Tenascin,
pubmed-meshheading:19738457-Tumor Markers, Biological
|
pubmed:year |
2009
|
pubmed:articleTitle |
Tenascin-X is a novel diagnostic marker of malignant mesothelioma.
|
pubmed:affiliation |
Department of Pathology, Norwegian Radium Hospital, Norway.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|